Cheap Wegovy Alternative 2026: Compounded Semaglutide from $99/Month
Wegovy costs $1,300–$1,500/month without insurance. Compounded semaglutide contains the same active ingredient and is available from $99/month through Trimi. This guide explains how and why.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This guide covers Wegovy's pricing, why compounded semaglutide is so much cheaper, and how to access it through Trimi's $99/month program.
Quick links: Semaglutide treatment, Ozempic alternative guide, and why compounded semaglutide is affordable.
More on Affordable GLP-1 Access
Ozempic Alternative for $99/Month
Same semaglutide as Ozempic at 90% less cost.
Why Is Compounded Semaglutide So Cheap?
The real economics behind compounded GLP-1 pricing.
Get a Semaglutide Prescription Today
Same-day online consultation — how fast Trimi's process is.
Start Semaglutide This Week
Step-by-step from signup to first injection.
The Wegovy Price Wall
Wegovy launched in June 2021 with a list price of $1,349 per month. By 2026, its price has only increased. For patients without insurance that specifically covers obesity medications — and that is the majority of commercially insured patients, plus nearly all Medicare beneficiaries — Wegovy's cost is simply unreachable for most American households.
The clinical evidence for Wegovy is compelling. The STEP program of clinical trials demonstrated an average 14.9% reduction in body weight with once-weekly semaglutide 2.4mg over 68 weeks. For a 250-pound person, that translates to roughly 37 pounds of weight loss. These are results that lifestyle intervention alone rarely achieves and that previously required bariatric surgery to reliably produce.
Yet the people who most need effective weight loss treatment are often those least able to pay $1,349 per month. Obesity disproportionately affects lower-income populations, and insurance coverage for obesity medications remains inconsistent and restricted. The result is a treatment gap: a medication that could transform health outcomes for millions, priced out of reach for most.
Price comparison in 2026: Wegovy list price approximately $1,349/month. Compounded semaglutide through Trimi: $99/month — a saving of over $1,200 per month, or $14,400 per year.
What Makes Wegovy Different from Other Semaglutide Products
Wegovy, Ozempic, and compounded semaglutide all contain the same active molecule: semaglutide. The differences between them are regulatory, commercial, and presentational rather than pharmacological.
Ozempic is approved by the FDA specifically for type 2 diabetes management at doses up to 2mg. Wegovy is the same semaglutide formulation approved for chronic weight management at doses up to 2.4mg. Novo Nordisk received a separate FDA approval for Wegovy, which allowed them to market it specifically for obesity — and to price it at a premium over Ozempic.
Both drugs use Novo Nordisk's proprietary auto-injector pen, their stabilizing excipients, and their manufacturing infrastructure. Compounded semaglutide bypasses all of this. A licensed compounding pharmacy takes pharmaceutical-grade semaglutide API (active pharmaceutical ingredient), prepares it in the prescribed concentration, and fills it into vials for subcutaneous injection with a standard syringe. The semaglutide molecule that enters your bloodstream is chemically identical.
Wegovy's specific approval for obesity is valuable from a regulatory and coverage perspective — it is the labeling that allows insurers to cover it for obesity rather than only diabetes. But it does not make the semaglutide in Wegovy clinically superior to the semaglutide in compounded preparations. The molecule is the molecule.
Compounded Semaglutide: How the $99 Price Is Possible
The compounding model eliminates the cost layers that make Wegovy so expensive. When Novo Nordisk sells Wegovy, the price reflects their R&D investment, patent protection, FDA approval costs, branded marketing spend, the auto-injector device, and the margins of wholesalers, pharmacy benefit managers, and retail pharmacies. Each layer adds cost.
Compounding pharmacies buy pharmaceutical-grade semaglutide API from verified suppliers and prepare it on a per-prescription basis. There is no marketing budget, no proprietary device, no brand premium. The compounding pharmacy charges for their labor, materials, and quality controls. Trimi's streamlined telehealth model means provider costs are distributed efficiently across a large patient base. The result: $99 per month for a medication that is therapeutically equivalent.
For a detailed breakdown of the economics, see our guide to why compounded semaglutide costs $99 instead of $1,349. The full picture of compounding economics explains why quality and price are not inversely related in this case.
Insurance and Wegovy: The Real Coverage Picture
Novo Nordisk's savings card can reduce Wegovy's cost for commercially insured patients whose plans cover it, but the coverage landscape remains complicated. As of 2026:
- Medicare Part D does not cover weight loss medications under current law, including Wegovy, even with a separate obesity indication
- Medicaid coverage varies by state — most states do not cover obesity medications, though a small number have expanded coverage
- Commercial insurance covers Wegovy inconsistently — many plans exclude it, require prior authorization, or impose step therapy requirements that can take months to complete
- Even insured patients who get coverage approved often face high deductibles or co-pays that reduce but do not eliminate cost
- Insurance coverage can be revoked at the next plan year's formulary update without notice
Trimi's compounded semaglutide program sidesteps all of this. There is no insurance required, no prior authorization, no formulary review, and no coverage appeal process. The $99 monthly price is available to any eligible patient regardless of insurance status. For the millions of Americans on Medicare, Medicaid, or plans that exclude obesity medications, this is often the only genuinely affordable pathway to semaglutide treatment.
Starting Compounded Semaglutide Through Trimi
Getting started with compounded semaglutide at Trimi takes three steps: complete the health assessment, get approved, receive your medication. The entire process is online and typically takes one to two weeks from first registration to first injection.
Step 1: Complete the online health assessment
Answer questions about your weight history, medical conditions, current medications, and goals. This typically takes 10 to 15 minutes. There is no video call required — everything is asynchronous.
Step 2: Provider review and approval
A board-certified Trimi physician reviews your submission within 24 hours on business days. They evaluate clinical eligibility and, if you qualify, prescribe compounded semaglutide at the starting dose.
Step 3: Medication shipped to your door
Your prescription goes to Trimi's partner compounding pharmacy. Medication ships within 5 to 7 business days, arriving in temperature-controlled packaging with injection supplies and dosing instructions.
For a more detailed walk-through of getting started, including what to expect at each dose level and how to manage early side effects, see our quick-start guide to getting your first dose. If you have questions about timeline, the same-day consultation guide covers how fast the process can move.
Dose Titration: Wegovy vs Compounded Semaglutide
Wegovy follows a standard titration schedule designed to minimize gastrointestinal side effects during dose escalation. The same titration logic applies to compounded semaglutide. Your Trimi provider will prescribe doses that follow this standard protocol:
| Weeks | Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 0.25 mg weekly | Initiation — tolerance building |
| Weeks 5–8 | 0.5 mg weekly | Dose escalation |
| Weeks 9–12 | 1.0 mg weekly | Therapeutic range |
| Weeks 13–16 | 1.7 mg weekly | Approaching maintenance |
| Week 17+ | 2.4 mg weekly | Maintenance dose |
Patients transitioning from Wegovy continue at their current dose. There is no need to restart titration. Your Trimi provider confirms the appropriate compounded dose for your specific point in the titration schedule.
What Results to Expect
Semaglutide produces clinically significant weight loss in the majority of patients. In the STEP 1 trial, 86.4% of patients treated with semaglutide 2.4mg achieved at least 5% body weight loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15%. Average weight loss was 14.9% over 68 weeks — about 33 pounds for someone starting at 220 pounds.
Results vary by individual. Patients with type 2 diabetes tend to lose less weight than those without (consistent with STEP 2 data). Higher body weight at baseline, younger age, and consistent lifestyle support tend to be associated with better outcomes. Weight loss typically plateaus around months six to twelve at the maintenance dose.
Most patients notice appetite suppression within the first two weeks. Measurable weight loss is usually apparent by weeks four to six. The full effect develops over six to twelve months of treatment. For guidance on supporting your results, see our anti-inflammatory diet guide for GLP-1 users.
Frequently Asked Questions
What is a cheaper alternative to Wegovy in 2026?
The most direct cheaper alternative to Wegovy in 2026 is compounded semaglutide. Wegovy contains semaglutide 2.4mg as its active ingredient — and compounded semaglutide contains the identical molecule. Through telehealth providers like Trimi, compounded semaglutide is available starting at $99 per month, compared to Wegovy's list price of $1,300 to $1,500 per month without insurance. The clinical mechanism, expected weight loss outcomes, and side effect profile are the same.
Why is Wegovy so expensive?
Wegovy is priced at $1,349 per month at list price in the United States. This reflects Novo Nordisk's research investment, FDA approval costs for the specific obesity indication, patent protection that prevents generic competition, and multiple layers of pharmaceutical supply chain markup including wholesalers, pharmacy benefit managers, and retail pharmacies. For patients without insurance coverage for weight loss medications — the majority — that entire cost falls out of pocket.
Is compounded semaglutide as effective as Wegovy for weight loss?
The active ingredient in both is identical: semaglutide. The clinical evidence for semaglutide's weight loss efficacy — including the STEP 1 trial showing average 14.9% body weight reduction — is pharmacological evidence about the molecule itself, not about Wegovy's specific pen device or packaging. Compounded semaglutide delivered via subcutaneous injection activates the same GLP-1 receptors, produces the same appetite suppression, and is expected to produce equivalent clinical outcomes when dosed appropriately.
Does insurance cover Wegovy?
Coverage for Wegovy varies widely. As of 2026, Medicare Part D explicitly does not cover weight loss medications, though legislation has been introduced to change this. Most commercial insurance plans cover Wegovy inconsistently — some cover it with prior authorization and step therapy requirements; many do not cover it at all for weight management. Coverage for Wegovy as a diabetes treatment (using the Ozempic formulation) is more common, but coverage specifically for obesity is far less consistent. Trimi's compounded semaglutide requires no insurance and no prior authorization.
Can I get compounded semaglutide at the same dose as Wegovy?
Yes. Wegovy is prescribed at doses of 0.25mg, 0.5mg, 1mg, 1.7mg, and the maintenance dose of 2.4mg per week. Compounded semaglutide can be prepared at any of these doses. Your Trimi provider will prescribe the appropriate dose based on your clinical situation — whether you are starting fresh or transitioning from Wegovy at a specific point in the titration schedule.
How do I start compounded semaglutide if I have been denied coverage for Wegovy?
Insurance denials for Wegovy do not affect your access to compounded semaglutide through Trimi. The two are independent pathways. You complete Trimi's online health assessment, a board-certified provider evaluates your eligibility, and if approved, your medication ships from an accredited compounding pharmacy. No insurance, no prior authorization, and no coverage appeals required. Most patients who have been denied Wegovy coverage find Trimi's process significantly faster and less frustrating.
What are the side effects of compounded semaglutide?
The side effects of compounded semaglutide are the same as those documented for Wegovy in clinical trials, because the active molecule is identical. The most common side effects are gastrointestinal: nausea, constipation, diarrhea, and vomiting, most pronounced during dose escalation and diminishing over time. These typically subside within four to eight weeks. Serious side effects — including pancreatitis, gallbladder disease, and rare cases of thyroid tumors — are the same for compounded and brand-name semaglutide. Your Trimi provider will discuss these with you during your consultation.
Sources & References
- Wilding JPH et al. STEP 1: Once-weekly semaglutide in adults with overweight or obesity. NEJM, 2021.
- Ryan DH et al. STEP 3: Semaglutide with intensive behavioral intervention for weight loss. NEJM, 2021.
- Wegovy FDA prescribing information, 2023.
- FDA: Compounding and FDA — Questions and Answers.
- NABP compounding pharmacy accreditation standards.
- NIDDK: Prescription medications to treat overweight and obesity.
- CMS Medicare Part D drug coverage overview.
- FDA drug shortage database.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Trimi is a telehealth provider offering compounded GLP-1 medications — this article is intended to be informative and readers should consider all options alongside their own physician's guidance.